Background: There is no conclusion about the most important contributor to the upswing of locally advanced colorectal cancer (LACRC) survival. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database was extracted to identify colorectal adenocarcinoma cancer patients at stage II and III diagnosed in the two periods 1989-1990 and 2009-2010 Conclusions: Advancements in chemotherapy regimen were the main contributor to the upswing of CRC survival. The improvements in surgery had a limited effect on improvements in CRC survival.
Introduction
Colorectal cancer (CRC) is the third most common adult cancer in the world, with an estimated 1.8 million cases and 881,000 deaths annually by the GLOBOCAN estimate in 2018. 1 With advances in treatment technology over the past few decades, the survival of patients with locally advanced colorectal cancer (LACRC) has improved significantly.
Treatment for locally advanced colorectal cancer includes surgical resection, 2 chemotherapy 3 and/ or radiation therapy. 4 Advances in surgical resection techniques are attributed to updated surgical equipment and concepts. Total mesorectal excision (TME) and complete mesocolic excision (CME) have become the consensus of all colorectal surgeons. 5, 6 In addition, application of laparoscopy and robot-assisted laparoscopy contribute to the refinement of CRC surgery. 7, 8 Adjuvant chemotherapy for LACRC patients with high-risk stage II and III cancer has substantially evolved over the past decades, concomitant with progress in marketing of oxaliplatin, irinotecan, cetuximab
The main contributor to the upswing of survival in locally advanced colorectal cancer: an analysis of the SEER database and bevacizumab, as well as the concept of neoadjuvant therapy.
The uptake of TME or CME combined with adjuvant oncological treatment for locally advanced rectal cancer has reduced local recurrence rates and improved long-term survival. 9 However, which is the most important contributor to the upswing in CRC survival? There is no final conclusion yet. Exploration of this issue can provide research directions relating to CRC, or even all tumors, in the future.
Therefore, the aim of this study was to explore the main contributor to the upswing of survival in LACRC.
Materials and methods

Patients
Data in this retrospective analysis were extracted from the Surveillance, Epidemiology, and End Results (SEER) linked database. The SEER Program of the National Cancer Institute is an authoritative source of information on cancer incidence and survival in the USA that is updated annually. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 34.6% of the US population. 10 The target population was limited to patients with stage II and III colorectal adenocarcinoma diagnosed in the periods 1989-1990 and 2009-2010 , which includes 40,470 patients in total. All patients were followed for more than 5 years. Exclusion criteria were: (1) appendix tumor, (2) diagnosed at autopsy or on the death certificate. The final study sample contained 40,184 patients.
We selected the period 1989-1990 as a baseline for comparison because the management of LACRC started to evolve rapidly from the 1990s; 9 we chose patients from the period 2009-2010 since these were the patients with the most recent with 5-year follow up. In 1989-1990 CRC was defined using the third edition AJCC staging. However, in 2009-2010 the sixth edition of the AJCC staging was adopted. Therefore, we re-staged the N stage according to the number of positive lymph nodes. We defined N1 as 1-3 lymph nodes positive and N2 as more than 4 lymph nodes positive.
Methods
Intergroup comparisons were analyzed using Pearson's chi-squared test. The log-rank test was used to compare overall survival (OS) between different groups. A hazard ratio (HR) and a 95% confidence interval (CI) were evaluated by a single factor and a multivariate Cox proportional hazards regression model. Univariate analysis of variables with significant differences was included in the Cox regression model for multivariate analysis. In order to eliminate the influence of other variables, we conducted propensity score matching (PSM). Statistical analyses were performed with IBM SPSS statistics trial v. 25.0 (IBM, Armonk, NY, USA). All reported p values lower than 0.05 were considered significant. 
Results
Patient characteristics
Survival analysis
The OS of patients with LACRC improved significantly due to advances in surgery combined with adjuvant therapy in the period between 1989-1990 and 2009-2010. The 5-year survival rate increased from 54.82% to 60.87% (p < 0.001, Figure 1(a) ), 56.81% to 66.89% (p < 0.001, 
The impact of surgical advancement on survival
We screened patients who underwent surgery without adjuvant therapy. In order to eliminate the influence of the other variables, PSM was conducted for an analysis of variables, including age, gender, race, differentiation and T and N stage (Supplementary Tables 1-3 ). The number of regional nodes examined did not match between the two groups, which can reflect the quality of surgery. We found that the surgical advancement was associated with the qualified rate of regional nodes, which improved by 41.76%, 48.90% and 43.84% in RCC, LCC and RC respectively. The log-rank test showed that OS of LCC was significantly increased with the development of surgical techniques (p = 0.015) (Figure 4(b) ). However, there was no significant effect of surgical advancement on the overall survival of RCC (p = 0.303, Figure 4 (a)) and RC (p = 0.660, Figure 4(c) ). Figure 5 (a); p = 0.006 in LCC, Figure 5(b) ; p = 0.001 in RC, Figure 5 (c)).
For exploration of the impact of radiotherapy on the survival of RC patients, those receiving radiotherapy were the target population. The variables for PSM were age, gender, race, differentiation, T stage, N stage, chemotherapy, surgery and the number of RNE (Supplementary Table 7) . Adjuvant radiotherapy was associated with an increased OS from 57.54% to 67.36% (p = 0.001, Figure 6 ).
Discussion
To the best of our knowledge, this study was the first to look into the main reason for the improvement of survival in LACRC. We selected patients with LACRC in the periods 1989-1990 and 2009-2010 , explored the relative importance of prognostic factors by a Cox regression model, and compared the effects of surgery and adjuvant therapy on survival after PSM. We believe that research on the progress of treatment can be fundamental to guiding the improvement of current treatment options. Also, successful experience in CRC treatment can be regarded as a reference for other tumors.
Although decreasing, the HR of non-surgical treatment was still the highest among various treatment methods. Therefore, it is still undoubted that surgery is the first-choice treatment for CRC. surgical resection, like TME and CME. Unfortunately, patient survival of RCC and RC did not improve significantly with advances in surgery, while LCC patients may benefit from CME and/or advanced equipment. Although many researchers reported that laparoscopic colectomy, which was widely used in the field of colorectal surgery in 2009-2010, significantly improves the short-term outcomes of patients, 11-14 the short-term survival rate in 2009-2010 was lower than that in 1989-1990. Therefore, surgeons need to pay more attention to the shortterm survival rate after surgery in future research, especially for patients who need surgery only, even though the scope of surgical resection can be considered to be appropriately restricted. TME was proposed by Heald and colleagues in 1982 15 and has become the standard for surgery of RC after more than 20 years of practice. 16 Owing to the successful experience of TME, CME was quickly recognized by colorectal surgeons, and was initially introduced in 2009. 17, 18 Therefore, both colon and rectal cancer can benefit from advances in surgical equipment, but the revolutionary concept was only proposed for the treatment of colon cancer between 1989-1990 and 2009-2010 . The values of HR and 95% CI for RC surgery varied minimally in our Cox regression model from 1989-1990 to 2009-2010; on the contrary, the change was huge in colon cancer. Therefore, we considered that advances in surgical equipment may be beneficial to the stability of operations, but the revolutionary surgical concept was the real engine for surgical progress.
More and more attention to adjuvant therapy is paid in modern medicine. The proportion of LACRC patients receiving chemotherapy and/or FOLFOX (oxaliplatin/5-FU/leucovorin) has become the first-line treatment for CRC in the 21st century. 20 We found that there was no intersection about the 95% CIs of chemotherapy between the two groups. Meanwhile, OS of LACRC patients who underwent surgery with chemotherapy improved significantly (p = 0.017 in RCC; p = 0.006 in LCC; p = 0.001 in RC) after PSM, suggesting that the advancements in chemotherapy regimen are the root cause of the improvement in CRC survival.
Further investigations to explore the effects of radiotherapy on survival of CRC are needed.
Although the OS of patients with RC who received radiotherapy in 2009-2010 was better than that in 1989-1990, the effects of chemotherapy cannot be ruled out. And radiotherapy cannot serve as a good prognostic factor in the Cox regression model. Specifically, patients who underwent radiotherapy had worse survival than those who did not undergo radiotherapy in RCC. Therefore, we tend to believe that radiotherapy alone cannot improve the RC survival. But we also cannot ignore the effect of radiotherapy on sphincter preservation in low rectal cancer.
The interesting findings of this study include: (1) although advancements in surgical treatment had not significantly prolonged the survival of CRC, surgeons should explore a more appropriate area of surgical resection and improve short-term outcomes without affecting the long-term survival of LACRC; (2) effective drugs are the key to cancer treatment since chemotherapy is the main contributor to the progress in treatment of CRC; (3) oncologists should consider whether the administration of radiotherapy can be abandoned for patients with mid/low rectal cancer if radiotherapy does not affect sphincter preservation. Access to only retrospective data was the main limitation of this study.
Conclusion
Advancements of chemotherapy regimen were the main contributor to the upswing in CRC survival. The improvements in surgery had a limited effect on improvements in CRC survival. The short-term survival of LACRC patients in 2009-2010 was even lower than that in 1989-1990. 
